Adam Gazzaley, MD, PhD & Digital Medicine Akili
His unconventional journey to bridge the gap between neuroscience and technology
Dr. Gazzaley founded Akili which is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine.
Recently, his company has raised additional $13 MM, bringing total series C funding to $68 MM.
To see a list of other highlighted UCSF startups, click the category heading.
Medical Therapeutics
Cancer
Apricity Therapeutics
Araxes Pharma
AtlasMedx
Calithera Biosciences
eFFECTOR Therapeutics
Exelixis
Fortis Therapeutics
Halozyme Therapeutics
K-Gen
KSQ Therapeutics
Metkine Therapeutics
Nalo Therapeutics
OncoSynergy
Orphagen Pharmaceuticals
Pionyr Immunotherapeutics
Principia Biopharma
Prosetta Biosciences
Rescue Therapeutics
Telo Therapeutics
Vivace Therapeutics
Cardiovascular Diseases
Catalyst Biosciences
Global Blood Therapeutics
InCarda Therapeutics
Cell Therapy
Cell Design Labs (acquired by Gilead)
Central Nervous System
Epiodyne
MedGenesis Therapeutix
Mitokinin
Neuraltus Pharmaceuticals
Neurona Therapeutics
Optikira
PharmatrophiX
Principia Biopharma
Prosetta Biosciences
Voyager Therapeutics
Hearing Disorders
Jacaranda Biosciences
Infectious Diseases
Prosetta Biosciences
TheraBiol
Immunology
Inception 5 (acquired by Roche)
Orphagen Pharmaceuticals
Pliant Therapeutics
Principia Biopharma
Siolta Therapeutics
Metabolic Disorders
Empire Biotechnologies
Optikira
Ophthalmology
Optikira
Orphan Diseases
Epygenix Therapeutics
Orphagen Pharmaceuticals
Respiratory
Aer Therapeutics
